Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + etoposide + cisplatin + toripalimab
- Development stage
- Preclinical
- Lead developer
- HUTCHMED
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination regimen consisting of four agents: surufatinib, etoposide, cisplatin, and toripalimab. Surufatinib is an oral small-molecule tyrosine kinase inhibitor that targets VEGFR1/2/3, FGFR1, and CSF1R to inhibit tumor angiogenesis and modulate the immune microenvironment[6][9]. Etoposide is a cytotoxic chemotherapeutic agent that inhibits topoisomerase II, leading to DNA strand breaks. Cisplatin is a platinum-based chemotherapy drug that forms DNA crosslinks and induces apoptosis in cancer cells. Toripalimab is a monoclonal antibody immune checkpoint inhibitor targeting PD-1 on T cells to enhance anti-tumor immunity[7][10]. This combination leverages antiangiogenic effects (surufatinib), cytotoxic chemotherapy (etoposide/cisplatin), and immunotherapy (toripalimab) for synergistic antitumor activity.
- Brand names
- Sulanda (surufatinib)Loqtorzi (toripalimab)
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)TOP2A (DNA topoisomerase II)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on surufatinib + etoposide + cisplatin + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + etoposide + cisplatin + toripalimab.